Intraoperative Neuromonitoring in Percutaneous Spinal Cord Stimulator Placement.


Journal

Neuromodulation : journal of the International Neuromodulation Society
ISSN: 1525-1403
Titre abrégé: Neuromodulation
Pays: United States
ID NLM: 9804159

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 21 05 2018
revised: 14 09 2018
accepted: 27 09 2018
pubmed: 18 11 2018
medline: 30 4 2019
entrez: 17 11 2018
Statut: ppublish

Résumé

Placement of spinal cord stimulation (SCS) paddles under general anesthesia using intraoperative neuromonitoring (IONM) has been shown to be associated with equivocal or superior clinical outcomes in comparative studies. The value of IONM in percutaneous permanent SCS placement has not been demonstrated. Outcomes for patients under percutaneous SCS placement performed with IONM were prospectively collected. Descriptive outcomes included numerical rating scale (NRS), the Oswestry disability index (ODI), McGill pain questionnaire, pain catastrophizing scale score (PCS), and Beck Depression Inventory. We also assessed satisfaction, willingness to repeat surgery, complication rates, and opioid use at baseline and follow-up using chart data and the New York Internet System for Tracking Over-Prescribing data base. The mean follow-up for our 46 patients was 22.04 ± 15.03 months (range 6-52 months). There were 10 patients (21.3%) who underwent revisions or removals with a mean time to revision/explant of 11.4 ± 11.7 months. About 85% of patients were satisfied with surgery. A total of 24 of 46 patients were on opioids at baseline. Following surgery, 17 of 24 (70.83%) patients demonstrated decreased opioid use in Morphine Milligram Equivalents. Of the 17 patients that reduced opioid use, 14 (82.35%) ceased opioid use entirely. Improvement from baseline was noted in NRS, ODI, and PCS (p < .05). Permanent percutaneous implantation of a SCS system using IONM with general anesthesia demonstrates results within range to those in the literature. Patients demonstrated statistically significant improvement in outcomes and opioid use was reduced in 71% of patients who were using opioids at baseline. We recommend its use in patients with morbid obesity, sleep apnea, and considerable anxiety. Further research is warranted to define the possible future role for percutaneous SCS implantation under IONM.

Identifiants

pubmed: 30444284
doi: 10.1111/ner.12886
pii: S1094-7159(21)01910-3
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

341-346

Informations de copyright

© 2018 International Neuromodulation Society.

Auteurs

Roy Hwang (R)

Department of Neurosurgery, Albany Medical College, Albany, NY, USA.

Nicholas Field (N)

Department of Neurosurgery, Albany Medical College, Albany, NY, USA.

Vignessh Kumar (V)

Department of Neurosurgery, Albany Medical College, Albany, NY, USA.

Steven Paniccioli (S)

Impulse Monitoring, Inc., Columbia, MD, USA.

Rachel Grey (R)

Impulse Monitoring, Inc., Columbia, MD, USA.

Michael Briotte (M)

Impulse Monitoring, Inc., Columbia, MD, USA.

Vishad Sukul (V)

Department of Neurosurgery, Albany Medical College, Albany, NY, USA.

Julie G Pilitsis (JG)

Department of Neurosurgery, Albany Medical College, Albany, NY, USA.
Department of Neuroscience and Experimental Therapeutics, Albany Medical College, Albany, NY, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH